vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-970Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРЕЗУЛЬТАТЫ МАССОВОГО СКРИНИНГА НОВОРОЖДЕННЫХ НА МУКОВИСЦИДОЗ В МОСКВЕRESULTS OF MASS SCREENING OF NEWBORNS WITH CYSTIC FIBROSIS IN MOSCOWКусоваЗ.А.KusovaZ.A.ПетроваН.В.PetrovaN.V.ВасильеваТ.А.Vasil'evaT.A.КаширскаяН.Ю.KashirskayaN.Yu.ЗинченкоР.А.ZinchenkoR.A.КапрановН.И.KapranovN.I.Медико-генетический научный центр РАМН, МоскваРоссияMedical Genetics Scientific Center, Russian Academy of Medical Sciences, MoscowRussian Federation20101709201596Вопросы современной педиатрии2630Copyright © Кусова З., Петрова Н., Васильева Т., Каширская Н., Зинченко Р., Капранов Н., 20102010Кусова З., Петрова Н., Васильева Т., Каширская Н., Зинченко Р., Капранов Н.Kusova Z., Petrova N., Vasil'eva T., Kashirskaya N., Zinchenko R., Kapranov N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/970ReferencesBrice P., Jarrett J., Mugford M. Genetic screening for cystic fibrosis: An overview of the science and the economics. J. Cystic Fibrosis. 2007; 6: 255–261.Brice P., Jarrett J., Mugford M. Genetic screening for cystic fibrosis: An overview of the science and the economics. J. Cystic Fibrosis. 2007; 6: 255–261.Castellani C., Southern K.W., Brownlee K. et al. European best practice guidelines for cystic fibrosis neonatal screening. J. Cystic Fibrosis. 2009; 8: 153–173.Castellani C., Southern K.W., Brownlee K. et al. European best practice guidelines for cystic fibrosis neonatal screening. J. Cystic Fibrosis. 2009; 8: 153–173.Kharrazi M., Kharrazi L.D. Delayed diagnosis of cystic fibrosis and the family perspective. J. Pediatr. 2005; 147: 21–25.Kharrazi M., Kharrazi L.D. Delayed diagnosis of cystic fibrosis and the family perspective. J. Pediatr. 2005; 147: 21–25.Муковисцидоз. Современные достижения и актуальные проблемы. Методические рекомендации. Издание третье (первое 2001) переработанное и дополненное. Под ред. Капранова Н.И., Каширской Н.Ю. М.: 4ТЕ Арт. 2008. 124 с.Муковисцидоз. Современные достижения и актуальные проблемы. Методические рекомендации. Издание третье (первое 2001) переработанное и дополненное. Под ред. Капранова Н.И., Каширской Н.Ю. М.: 4ТЕ Арт. 2008. 124 с.Cheillan D., Vercherat M., Chevalier–Porst F. et al. False-positive results in neonatal screening for cystic fibrosis based on a three stage protocol (IRT/DNA/IRT): should we adjust IRT cut-off to ethnic origin? J. Inherit Metab. Disease. 2005; 28: 813–818.Cheillan D., Vercherat M., Chevalier–Porst F. et al. False-positive results in neonatal screening for cystic fibrosis based on a three stage protocol (IRT/DNA/IRT): should we adjust IRT cut-off to ethnic origin? J. Inherit Metab. Disease. 2005; 28: 813–818.Rock M.J., Mischler E.H., Farrell P.M. et al. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990; 85 (6): 1001–1007.Rock M.J., Mischler E.H., Farrell P.M. et al. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990; 85 (6): 1001–1007.Comeau A.M., Parad R.B., Dorkin H.L. et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a CF newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004; 113(6): 1573–1581.Comeau A.M., Parad R.B., Dorkin H.L. et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a CF newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004; 113(6): 1573–1581.Crossley J.R., Elliott R.B., Smith P.A. Dried blood spot screening for cystic fibrosis in the newborn. Lancet. 1979; 1(8114): 472–474.Crossley J.R., Elliott R.B., Smith P.A. Dried blood spot screening for cystic fibrosis in the newborn. Lancet. 1979; 1(8114): 472–474.Giusti R. New York State Cystic Fibrosis Newborn Screening Consortium. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population. Pediatr. Pulmonol. 2008; 43: 638–641.Giusti R. New York State Cystic Fibrosis Newborn Screening Consortium. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population. Pediatr. Pulmonol. 2008; 43: 638–641.Heeley A.F., Fagan D.G. Trisomy 18, cystic fibrosis, and blood immunoreactive trypsin. Lancet. 1984; 1: 169–170.Heeley A.F., Fagan D.G. Trisomy 18, cystic fibrosis, and blood immunoreactive trypsin. Lancet. 1984; 1: 169–170.Priest F.J., Nevin N.C. False positive results with immunoreactive trypsinogen screening for cystic fibrosis owing to trisomy 13. J. Med. Genet. 1991; 28: 575–576.Priest F.J., Nevin N.C. False positive results with immunoreactive trypsinogen screening for cystic fibrosis owing to trisomy 13. J. Med. Genet. 1991; 28: 575–576.Sarles J., Barthellemy S., Férec C. et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch. Dis. Child Fetal. Neonatal Ed. 1999; 80 (2): 118–122.Sarles J., Barthellemy S., Férec C. et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch. Dis. Child Fetal. Neonatal Ed. 1999; 80 (2): 118–122.Iovanna J.L., Férec C., Sarles J., Dagorn J.C. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. Acad. Sci. 1994; 317 (6): 561–564.Iovanna J.L., Férec C., Sarles J., Dagorn J.C. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. Acad. Sci. 1994; 317 (6): 561–564.Толстова В.Д., Каширская Н.Ю., Капранов Н.И. Массовый скрининг новорожденных на муковисцидоз в России. Фарматека. 2008; 1: 1–5.Толстова В.Д., Каширская Н.Ю., Капранов Н.И. Массовый скрининг новорожденных на муковисцидоз в России. Фарматека. 2008; 1: 1–5.Животовский Л.А. Популяционная биометрия. М.: Наука. 1991. 271 с.Животовский Л.А. Популяционная биометрия. М.: Наука. 1991. 271 с.Петрова Н.В. Определение относительных частот некоторых мутаций гена CFTR и анализ гаплотипов сцепленных с ними ДНК–маркерных локусов в Популяции России. Автореф. дис. … канд. биол. наук. М. 1996. 24 с.Петрова Н.В. Определение относительных частот некоторых мутаций гена CFTR и анализ гаплотипов сцепленных с ними ДНК–маркерных локусов в Популяции России. Автореф. дис. … канд. биол. наук. М. 1996. 24 с.Петрова Н.В., Тимковская Е.Е., Зинченко Р.А., Гинтер Е.К. Анализ частоты некоторых мутаций в гене CFTR в разных популяциях России. Медицинская генетика. 2006; 2: 32–39.Петрова Н.В., Тимковская Е.Е., Зинченко Р.А., Гинтер Е.К. Анализ частоты некоторых мутаций в гене CFTR в разных популяциях России. Медицинская генетика. 2006; 2: 32–39.Southern K.W., Munck A., Pollit R. et al. A survey of newborn screening for cystic fibrosis in Eur. J. Cystic Fibrosis. 2007; 6: 57–65.Southern K.W., Munck A., Pollit R. et al. A survey of newborn screening for cystic fibrosis in Eur. J. Cystic Fibrosis. 2007; 6: 57–65.
The authors declare that there are no conflicts of interest present.